Bristol-Myers Squibb (NYSE:BMY) Stock Price Up 0%

Bristol-Myers Squibb (NYSE:BMY - Get Free Report)'s stock price traded up 0% on Friday . The company traded as high as $41.14 and last traded at $40.77. 2,787,388 shares traded hands during trading, a decline of 82% from the average session volume of 15,586,995 shares. The stock had previously closed at $40.75.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an "equal weight" rating in a research note on Thursday, April 18th. StockNews.com lowered Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Thursday, June 27th. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. BMO Capital Markets dropped their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a "market perform" rating for the company in a research note on Friday, April 26th. Finally, Barclays dropped their price target on Bristol-Myers Squibb from $43.00 to $41.00 and set an "equal weight" rating for the company in a research note on Wednesday. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $59.50.

Bristol-Myers Squibb Stock Performance

The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The business has a fifty day simple moving average of $41.99 and a 200-day simple moving average of $47.47. The firm has a market cap of $82.04 billion, a P/E ratio of -13.15, a P/E/G ratio of 14.07 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same period last year, the company earned $2.05 earnings per share. The company's revenue was up 4.7% on a year-over-year basis. On average, sell-side analysts predict that Bristol-Myers Squibb will post 0.58 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be issued a dividend of $0.60 per share. The ex-dividend date is Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 5.93%. Bristol-Myers Squibb's payout ratio is presently -77.42%.

Hedge Funds Weigh In On Bristol-Myers Squibb

Institutional investors and hedge funds have recently modified their holdings of the stock. VisionPoint Advisory Group LLC boosted its position in shares of Bristol-Myers Squibb by 300.5% during the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company's stock valued at $43,000 after buying an additional 553 shares during the last quarter. WNY Asset Management LLC boosted its position in shares of Bristol-Myers Squibb by 14.8% during the third quarter. WNY Asset Management LLC now owns 8,103 shares of the biopharmaceutical company's stock valued at $470,000 after buying an additional 1,047 shares during the last quarter. Anchor Investment Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at $1,111,000. Symmetry Partners LLC boosted its position in shares of Bristol-Myers Squibb by 16.4% during the fourth quarter. Symmetry Partners LLC now owns 22,145 shares of the biopharmaceutical company's stock valued at $1,134,000 after buying an additional 3,117 shares during the last quarter. Finally, Trust Co. of Toledo NA OH boosted its position in shares of Bristol-Myers Squibb by 1.9% during the fourth quarter. Trust Co. of Toledo NA OH now owns 33,796 shares of the biopharmaceutical company's stock valued at $1,734,000 after buying an additional 635 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.